Sarsasapogenin

Drug Profile

Sarsasapogenin

Alternative Names: Cogane; JNX-1001; PYM-50028; Smilagenin

Latest Information Update: 26 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phytopharm
  • Developer IXICO
  • Class Antidementias; Herbal medicines; Neuroprotectants; Nootropics; Small molecules; Steroid sapogenins
  • Mechanism of Action Brain derived neurotrophic factor agonists; Glial cell line-derived neurotrophic factor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alzheimer's disease; Amyotrophic lateral sclerosis; Glaucoma; Parkinson's disease

Most Recent Events

  • 23 May 2013 Phytopharm conducts discussions with external parties for further development of sarsasapogenin under licensing arrangements
  • 28 Feb 2013 Efficacy data from the phase II CONFIDENT-PD trial in Parkinson's disease released by Phytopharm
  • 18 Apr 2012 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Phytopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top